,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,NKX2-5,"CSX, CSX1, NKX2.5, NKX2E, NKX4-1",ENSG00000183072,NK2 homeobox 5,5,173232109-173235357,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA065034,,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,126,heart muscle: 32.7;spleen: 14.5,"breast,placenta,urinary bladder: 0.1",Cell line enhanced,,HEK93: 27.1;NTERA-2: 10.7;U-2 OS: 24.8;U-251 MG: 15.4
1,CR2,"C3DR, CD21",ENSG00000117322,Complement C3d receptor 2,1,207454230-207489895,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002659, HPA052942, HPA060715",Enhanced,,,,Breast cancer:6.90e-4 (favourable),Mixed,Group enriched,21,appendix: 68.3;lymph node: 206.0;spleen: 100.2;tonsil: 153.8,kidney: 6.2,Cell line enhanced,,Daudi: 17.1;MOLT-4: 10.7;RPMI-8226: 3.2
2,FAM129C,"BCNP1, FLJ39802",ENSG00000167483,Family with sequence similarity 129 member C,19,17523301-17553839,Predicted intracellular proteins,Evidence at protein level,HPA043277,Approved,,,,,Mixed,Group enriched,15,appendix: 13.9;bone marrow: 11.3;lymph node: 28.2;spleen: 36.9;tonsil: 9.4,gallbladder: 1.3,Group enriched,20.0,Daudi: 35.8;REH: 23.1;U-698: 21.5
3,MS4A1,"B1, Bp35, CD20, MS4A2",ENSG00000156738,Membrane spanning 4-domains A1,11,60455752-60470760,"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB000015, HPA014341, HPA014391",Enhanced,,Supported,Plasma membrane,Breast cancer:4.34e-5 (favourable),Mixed,Group enriched,15,appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8,urinary bladder: 38.3,Group enriched,19.0,Daudi: 534.8;U-698: 258.0
4,FCRL3,"CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e",ENSG00000160856,Fc receptor like 3,1,157674321-157700857,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA048022,Enhanced,,,,,Mixed,Group enriched,13,appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3,urinary bladder: 2.8,Cell line enriched,7.0,Daudi: 6.9
5,OTOA,"CT108, DFNB22",ENSG00000155719,Otoancorin,16,21678514-21760729,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041405,Uncertain,,,,,Not detected,Group enriched,13,spleen: 2.6;testis: 6.0,epididymis: 0.3,Not detected,,
6,CD19,,ENSG00000177455,CD19 molecule,16,28931939-28939346,"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,CAB016110,Enhanced,,,,,Mixed,Group enriched,11,appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3,urinary bladder: 5.5,Group enriched,40.0,Daudi: 103.6;REH: 70.5;U-698: 22.6
7,GPR88,,ENSG00000181656,G protein-coupled receptor 88,1,100538137-100542018,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at transcript level,HPA007488,,Approved,,,,Tissue enriched,Group enriched,11,breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4,prostate: 0.6,Group enriched,8.0,HSkMC: 1.1;SCLC-21H: 2.3
8,BLK,MGC10442,ENSG00000136573,"BLK proto-oncogene, Src family tyrosine kinase",8,11494001-11564604,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005093, HPA069571",Approved,,Approved,Nucleoplasm,,Mixed,Group enriched,10,appendix: 22.0;lymph node: 61.2;spleen: 40.6;tonsil: 51.4,urinary bladder: 4.3,Group enriched,6.0,Daudi: 99.9;REH: 39.4;RPMI-8226: 47.4;U-698: 55.4;U-87 MG: 29.9
9,CLEC17A,FLJ45910,ENSG00000187912,C-type lectin domain family 17 member A,19,14583084-14611157,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,10,appendix: 16.6;lymph node: 30.4;spleen: 19.2;tonsil: 28.4,urinary bladder: 2.3,Group enriched,11.0,Daudi: 6.8;U-698: 12.0
10,CSAG3,CSAG3A,ENSG00000268916,CSAG family member 3,X,152753921-152760222,Predicted intracellular proteins,Evidence at transcript level,HPA078264,,,Approved,Vesicles,,Mixed,Group enriched,10,lymph node: 1.7;skin: 1.2;spleen: 1.9;testis: 4.2,"adipose tissue,lung,placenta: 0.2",Cell line enhanced,,HDLM-2: 23.7;HMC-1: 22.9;SH-SY5Y: 35.8;SK-BR-3: 23.6;U-2 OS: 25.4;U-266/70: 61.5;U-266/84: 30.6
11,FCRLA,"FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595",ENSG00000132185,Fc receptor like A,1,161706972-161714352,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB016545,Enhanced,,,,,Tissue enriched,Group enriched,10,appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7,urinary bladder: 6.2,Cell line enhanced,,Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6
12,P2RX5,"LRH-1, P2X5",ENSG00000083454,Purinergic receptor P2X 5,17,3672199-3696404,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021948, HPA067827",Supported,,Supported,Cytosol,,Mixed,Group enriched,10,appendix: 40.9;lymph node: 89.8;spleen: 74.3;tonsil: 47.1,bone marrow: 6.2,Cell line enhanced,,Daudi: 36.5;RPMI-8226: 40.2;U-698: 32.6
13,TNFRSF13C,"BAFFR, CD268",ENSG00000159958,TNF receptor superfamily member 13C,22,41922023-41926818,"CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA003246, CAB008380",Enhanced,,Uncertain,Nucleus,Cervical cancer:4.44e-7 (favourable),Mixed,Group enriched,10,appendix: 22.9;lymph node: 46.1;spleen: 43.5;tonsil: 49.9,bone marrow: 4.0,Cell line enhanced,,REH: 19.1;U-698: 7.7
14,CD72,"CD72b, LYB2",ENSG00000137101,CD72 molecule,9,35609533-35646810,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002505, HPA044658",Enhanced,,Approved,Nucleus<br>Mitochondria,Renal cancer:2.49e-8 (unfavourable),Expressed in all,Group enriched,8,appendix: 25.1;lymph node: 71.1;spleen: 64.7;tonsil: 42.6,gallbladder: 6.2,Cell line enhanced,,Daudi: 13.0;Karpas-707: 8.1;REH: 7.0;U-698: 27.7
15,CPLX3,CPX-III,ENSG00000213578,Complexin 3,15,74826547-74831802,Predicted intracellular proteins,Evidence at protein level,CAB079003,,Supported,,,,Not detected,Group enriched,8,prostate: 143.7;spleen: 74.6,cerebral cortex: 12.8,Cell line enhanced,,Daudi: 1.6;Karpas-707: 1.4;SCLC-21H: 1.0
16,FCRL2,"CD307b, FCRH2, IRTA4, SPAP1",ENSG00000132704,Fc receptor like 2,1,157745733-157777132,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,8,appendix: 16.3;lymph node: 28.4;spleen: 25.9;tonsil: 23.7,rectum: 3.0,Group enriched,27.0,Daudi: 9.2;U-266/70: 2.0;U-698: 7.2
17,MCF2L2,"ARHGEF22, KIAA0861",ENSG00000053524,MCF.2 cell line derived transforming sequence-like 2,3,183178043-183428778,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,"HPA038946, HPA038947",Uncertain,,Approved,Plasma membrane<br>Cytosol,,Not detected,Group enriched,8,adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7,prostate: 1.0,Cell line enhanced,,HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1
18,BTLA,"BTLA1, CD272",ENSG00000186265,B and T lymphocyte associated,3,112463968-112499561,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA047211, HPA062029",Enhanced,,,,,Mixed,Group enriched,7,appendix: 14.1;lymph node: 29.3;spleen: 14.6;tonsil: 24.7,urinary bladder: 3.0,Cell line enhanced,,U-698: 1.3
19,CXCL13,"ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13",ENSG00000156234,C-X-C motif chemokine ligand 13,4,77511753-77611834,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA052613,Uncertain,,,,"Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable)",Expressed in all,Group enriched,7,appendix: 163.3;lymph node: 599.9;spleen: 423.8;tonsil: 395.7,urinary bladder: 57.9,Cell line enhanced,,U-266/70: 1.0
20,FCER2,"CD23, CD23A, CLEC4J, FCE2",ENSG00000104921,Fc fragment of IgE receptor II,19,7688758-7702146,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002624, HPA008928",Enhanced,,,,,Mixed,Group enriched,7,appendix: 21.9;lymph node: 47.4;spleen: 52.6;tonsil: 38.0,adipose tissue: 5.8,Cell line enriched,16.0,HDLM-2: 416.1
21,LTB,"p33, TNFC, TNFSF3",ENSG00000227507,Lymphotoxin beta,6,31580525-31582522,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA048884,Approved,,Approved,Centrosome,"Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable)",Expressed in all,Group enriched,7,appendix: 18.6;lymph node: 22.1;spleen: 25.8;tonsil: 10.1,bone marrow: 2.6,Cell line enhanced,,Daudi: 20.4;HDLM-2: 15.0;NB-4: 11.8;REH: 16.1;U-698: 14.4
22,RP11-277P12.6,,ENSG00000255641,,12,10412312-10436001,Predicted membrane proteins,Evidence at transcript level,HPA062570,Uncertain,,,,,Not detected,Group enriched,7,cerebral cortex: 8.2;spleen: 6.1,bone marrow: 1.0,Cell line enriched,5.0,HeLa: 5.8
23,SIGLEC11,,ENSG00000161640,Sialic acid binding Ig like lectin 11,19,49948985-49961172,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA060278,Approved,,,,,Mixed,Group enriched,7,ovary: 80.0;spleen: 31.7,adrenal gland: 8.1,Cell line enriched,15.0,HEL: 9.4
24,TLR10,CD290,ENSG00000174123,Toll like receptor 10,4,38772239-38782990,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,7,appendix: 21.1;lymph node: 51.7;spleen: 34.7;tonsil: 45.1,urinary bladder: 5.5,Group enriched,65.0,Daudi: 51.1;REH: 22.0;U-698: 17.6
25,CCR7,"BLR2, CD197, CDw197, CMKBR7, EBI1",ENSG00000126353,C-C motif chemokine receptor 7,17,40553769-40565472,"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB003796, HPA031383, HPA074467",Enhanced,,Supported,Mitochondria,"Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable)",Mixed,Group enriched,6,appendix: 88.8;lymph node: 97.1;spleen: 39.3;tonsil: 77.2,urinary bladder: 12.4,Cell line enriched,79.0,HDLM-2: 1284.5
26,CCR9,"CDw199, GPR-9-6, GPR28",ENSG00000173585,C-C motif chemokine receptor 9,3,45886504-45903177,"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB006839,Uncertain,,,,,Not detected,Group enriched,6,appendix: 1.4;duodenum: 3.8;small intestine: 5.7;spleen: 1.2,"lymph node,tonsil: 0.4",Cell line enriched,362.0,MOLT-4: 90.5
27,CD79A,"IGA, MB-1",ENSG00000105369,CD79a molecule,19,41877120-41881372,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB000019,Enhanced,,,,"Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)",Mixed,Group enriched,6,appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1,stomach: 63.3,Group enriched,23.0,Daudi: 1084.6;REH: 432.6;U-698: 905.8
28,CEACAM4,CGM7,ENSG00000105352,Carcinoembryonic antigen related cell adhesion molecule 4,19,41618971-41627074,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,6,appendix: 6.7;bone marrow: 13.9;spleen: 9.0,adipose tissue: 1.7,Cell line enriched,7.0,U-937: 3.2
29,CETP,BPIFF,ENSG00000087237,Cholesteryl ester transfer protein,16,56961850-56983845,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Group enriched,6,adipose tissue: 36.9;liver: 21.7;lymph node: 46.3;placenta: 50.4;spleen: 77.7,thyroid gland: 8.4,Cell line enhanced,,HEL: 2.4;HUVEC TERT2: 3.6;TIME: 2.1
30,CNR2,CB2,ENSG00000188822,Cannabinoid receptor 2,1,23870526-23913362,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,CAB009719,Uncertain,,,,,Tissue enriched,Group enriched,6,appendix: 3.1;lymph node: 8.7;spleen: 7.9;tonsil: 6.9,bone marrow: 1.0,Group enriched,5.0,Daudi: 3.8;HEL: 4.0;HMC-1: 17.3;U-698: 9.4
31,KLRC2,"CD159c, NKG2-C",ENSG00000205809,Killer cell lectin like receptor C2,12,10426854-10442300,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058052,,,Approved,Plasma membrane,,Tissue enriched,Group enriched,6,cerebral cortex: 17.3;spleen: 8.1,stomach: 2.1,Cell line enhanced,,HEL: 5.2;HeLa: 11.9;HSkMC: 3.0;U-87 MG: 2.8
32,NR5A1,"AD4BP, ELP, FTZ1, FTZF1, hSF-1, SF-1",ENSG00000136931,Nuclear receptor subfamily 5 group A member 1,9,124481236-124507430,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Group enriched,6,adrenal gland: 137.7;ovary: 36.3;spleen: 151.6,testis: 19.6,Group enriched,31.0,HEL: 73.5;Hep G2: 36.2;K-562: 17.7
33,SP140,"LYSP100-A, LYSP100-B",ENSG00000079263,SP140 nuclear body protein,2,230203110-230313215,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA006162, HPA067493",Enhanced,,Approved,Nucleoli fibrillar center<br>Mitochondria,,Mixed,Group enriched,6,appendix: 32.8;lymph node: 64.4;spleen: 38.3;tonsil: 50.7,urinary bladder: 7.6,Cell line enhanced,,Daudi: 22.1;HDLM-2: 48.5;Karpas-707: 18.0;RPMI-8226: 11.2
34,STAP1,"BRDG1, STAP-1",ENSG00000035720,Signal transducing adaptor family member 1,4,67558728-67607337,Predicted intracellular proteins,Evidence at protein level,HPA038529,Enhanced,,Uncertain,Nucleoplasm<br>Vesicles,,Tissue enriched,Group enriched,6,appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3,testis: 6.1,Cell line enhanced,,Daudi: 141.5;U-698: 60.7;U-937: 22.3
35,APLNR,"AGTRL1, APJ, APJR, FLJ90771",ENSG00000134817,Apelin receptor,11,57233577-57237314,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,CAB025842,Approved,,,,,Expressed in all,Group enriched,5,cerebral cortex: 82.7;placenta: 146.8;spleen: 161.6,adipose tissue: 24.9,Group enriched,22.0,AF22: 6.2;HEL: 5.0;K-562: 1.5;NTERA-2: 1.8
36,BANK1,"BANK, FLJ20706",ENSG00000153064,B-cell scaffold protein with ankyrin repeats 1,4,101411286-102074812,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA037002,Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Mixed,Group enriched,5,appendix: 45.9;lymph node: 96.8;spleen: 77.4;thyroid gland: 21.6;tonsil: 87.2,urinary bladder: 12.9,Cell line enhanced,,Daudi: 9.7;HEL: 9.5;HL-60: 7.6;U-266/70: 23.8
37,CD79B,"B29, IGB",ENSG00000007312,CD79b molecule,17,63928740-63932354,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA009178, CAB009751",Enhanced,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,Head and neck cancer:2.35e-4 (favourable),Expressed in all,Group enriched,5,appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1,bone marrow: 36.1,Group enriched,17.0,Daudi: 751.6;REH: 317.0;U-698: 986.5
38,CROCC2,,ENSG00000226321,"Ciliary rootlet coiled-coil, rootletin family member 2",2,240906330-240993311,Predicted intracellular proteins,Evidence at protein level,HPA048678,Enhanced,,,,,Tissue enhanced,Group enriched,5,fallopian tube: 8.6;spleen: 3.1,lung: 1.1,Cell line enhanced,,RPMI-8226: 1.9
39,FAM178B,LOC51252,ENSG00000168754,Family with sequence similarity 178 member B,2,96875882-96986592,Predicted intracellular proteins,Evidence at transcript level,"HPA042516, HPA062110",Uncertain,,Uncertain,Nuclear speckles<br>Golgi apparatus,,Tissue enriched,Group enriched,5,bone marrow: 11.4;epididymis: 6.7;spleen: 16.7;testis: 7.4,fallopian tube: 2.0,Cell line enhanced,,K-562: 23.0;RPMI-8226: 19.2;WM-115: 26.6
40,HLA-DOB,,ENSG00000241106,"Major histocompatibility complex, class II, DO beta",6,32812763-32817048,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA013846,Enhanced,,,,"Renal cancer:3.15e-5 (unfavourable), Ovarian cancer:4.17e-5 (favourable), Breast cancer:4.29e-4 (favourable)",Expressed in all,Group enriched,5,lymph node: 19.6;spleen: 18.6;tonsil: 30.7;urinary bladder: 8.3,colon: 3.5,Cell line enhanced,,Daudi: 37.8;U-698: 12.8;U-937: 6.1
41,KCNT1,"KCa4.1, KIAA1422, SLACK, Slo2.2",ENSG00000107147,Potassium sodium-activated channel subfamily T member 1,9,135702185-135795508,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA059880,Uncertain,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 11.6;ovary: 3.9;skeletal muscle: 3.8;spleen: 6.8,testis: 1.2,Cell line enhanced,,RPMI-8226: 1.2;SCLC-21H: 3.0
42,LILRB3,"CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB",ENSG00000204577,Leukocyte immunoglobulin like receptor B3,19,54216278-54223506,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Group enriched,5,adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8,placenta: 1.7,Not detected,,
43,LIMD2,MGC10986,ENSG00000136490,LIM domain containing 2,17,63695902-63701172,Predicted intracellular proteins,Evidence at protein level,HPA062867,,,Approved,Vesicles,Renal cancer:5.36e-11 (unfavourable),Expressed in all,Group enriched,5,appendix: 140.1;bone marrow: 71.2;lymph node: 255.5;spleen: 191.0;tonsil: 138.2,urinary bladder: 30.2,Cell line enhanced,,Daudi: 173.9;SH-SY5Y: 172.7;U-698: 174.0
44,NPAS1,"bHLHe11, MOP5, PASD5",ENSG00000130751,Neuronal PAS domain protein 1,19,47019820-47045775,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA043364, HPA072259",,Approved,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.9;skin: 4.4;spleen: 1.8;stomach: 2.6,lymph node: 0.6,Cell line enhanced,,HEK93: 10.1;NB-4: 11.4
45,PF4,"CXCL4, SCYB4",ENSG00000163737,Platelet factor 4,4,73981077-73982124,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB026008, HPA052485",Enhanced,,,,,Tissue enhanced,Group enriched,5,bone marrow: 53.7;spleen: 13.4,placenta: 6.5,Cell line enriched,13.0,HEL: 37.2
46,SEMA3D,"coll-2, Sema-Z2",ENSG00000153993,Semaphorin 3D,7,84995553-85186855,Predicted intracellular proteins,Evidence at protein level,HPA037522,Uncertain,,Approved,Golgi apparatus<br>Plasma membrane,,Mixed,Group enriched,5,spleen: 66.2;thyroid gland: 76.6,prostate: 13.4,Cell line enhanced,,fHDF/TERT166: 22.0;HaCaT: 25.4;TIME: 36.0
47,SIT1,SIT,ENSG00000137078,Signaling threshold regulating transmembrane adaptor 1,9,35649295-35650950,Predicted membrane proteins,Evidence at protein level,HPA018506,Enhanced,,,,"Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable)",Mixed,Group enriched,5,appendix: 24.6;lymph node: 56.1;spleen: 21.9;tonsil: 29.6,urinary bladder: 6.0,Cell line enhanced,,Daudi: 80.3;HDLM-2: 65.0;U-698: 70.1
48,TMEM156,FLJ23235,ENSG00000121895,Transmembrane protein 156,4,38966744-39032922,Predicted membrane proteins,Evidence at transcript level,,,,,,Breast cancer:4.09e-4 (favourable),Mixed,Group enriched,5,appendix: 11.8;lymph node: 27.8;spleen: 15.2;tonsil: 24.3;urinary bladder: 5.7,gallbladder: 3.0,Cell line enhanced,,Daudi: 28.3;HBEC3-KT: 59.6;hTERT-HME1: 48.9;PC-3: 34.1;U-698: 30.9
49,TUBB1,dJ543J19.4,ENSG00000101162,Tubulin beta 1 class VI,20,59019254-59026654,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004286, HPA043640, HPA046280",Approved,,,,,Not detected,Group enriched,5,bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5,gallbladder: 0.5,Cell line enriched,20.0,HEL: 24.9
